Consensi® is a combination drug that is indicated for the treatment of osteoarthritis (OA) pain and hypertension simultaneously. Consensi® is comprised of two FDA-approved drugs, celecoxib (the active ingredient in Pfizer’s Celebrex®) for the treatment of pain caused by OA, and amlodipine besylate (the active ingredient in Pfizer’s Norvasc®), a drug designed to treat hypertension.
The New Drug Application (NDA), was submitted by Kitov Pharmaceuticals in July 2017. The U.S. Food & Drug Administration (FDA) filed the NDA in September 2017, and approved Consensi® oral tablets for marketing on May 31, 2018.
On January 3, 2019, Coeptis Pharmaceuticals signed an exclusive marketing and distribution agreement with Kitov Pharmaceuticals for Consensi® in the U.S. market. Coeptis plans to launch Consensi® in early 2020.
For the most recent information, please visit http://www.consensi.com